Home > Publications database > Comparative study of liposomal amphotericin B, posaconazole, and micafungin for primary antifungal prophylaxis in pediatric patients with acute leukemia. > print

001     304095
005     20250831022512.0
024 7 _ |a 10.1007/s00432-025-06289-5
|2 doi
024 7 _ |a pmid:40848057
|2 pmid
024 7 _ |a 0301-1585
|2 ISSN
024 7 _ |a 0084-5353
|2 ISSN
024 7 _ |a 0171-5216
|2 ISSN
024 7 _ |a 1432-1335
|2 ISSN
024 7 _ |a altmetric:180547724
|2 altmetric
037 _ _ |a DKFZ-2025-01763
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Gottschlich, Anna Sophia
|b 0
245 _ _ |a Comparative study of liposomal amphotericin B, posaconazole, and micafungin for primary antifungal prophylaxis in pediatric patients with acute leukemia.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756189146_30612
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Invasive fungal diseases (IFDs) are a significant cause of morbidity and mortality in pediatric patients with hematologic malignancies including acute leukemia. Our study aimed to compare the efficacy of liposomal amphotericin B (L-AMB), posaconazole or micafungin as primary antifungal prophylaxis (PAP) in pediatric patients with acute leukemia.This retrospective observational study enrolled 95 pediatric patients with acute lymphoblastic leukemia (n = 70) or acute myeloid leukemia (n = 25), undergoing chemotherapy, including those undergoing allogeneic hematopoietic stem cell transplantation at the Department of Pediatrics, Jena University Hospital, Jena, Germany. PAP regimens included L-AMB (1 mg/kg/day or 3 mg/kg twice weekly, intravenously), posaconazole (100-300 mg/day, according to blood concentration, orally or intravenously) and micafungin (1 mg/kg/day or 3 mg/kg twice weekly, intravenously). Thirty-four patients (35.8%) received L-AMB, 37 patients (38.9%) received posaconazole, and 24 patients (25.3%) received micafungin. Patients with a history of IFD or concurrent or changing PAP were excluded. The primary endpoint was the occurrence of breakthrough IFD, while secondary endpoint included IFD-free survival. Statistical analyses were performed using Kaplan-Meier survival analysis, Gray's test and Cox regression to evaluate IFD-free survival.The overall incidence of IFD was 14.7% (14 of 95 patients). IFD developed in 10 of 33 patients (29.4%) receiving L-AMB, in 4 of 38 (10.8%) patients receiving posaconazole and in none of the patients receiving micafungin. IFD-free survival was 70.6% in the L-AMB group, 89.2% in the posaconazole group and 100% in the micafungin group (p = 0.005, log-rank test). Significant differences were also observed in the cumulative incidences of breakthrough IFDs (p = 0.006) assessed by Gray's test. In multivariate Cox analysis, dichotomized prophylaxis regimes (posaconazole or micafungin vs. L-AMB) were independently associated with a reduced risk of IFD (HR = 0.244; 95% CI 0.076-0.777; p = 0.017). Age ≥ 10 years predicted inferior IFD-free survival (HR = 3.665; 95% CI 1.224-10.980; p = 0.020).We found a significant difference in efficacy between the three antifungal prophylaxis regimens. In our study, micafungin achieved the lowest IFD breakthrough rate. However, multicenter clinical studies would be needed to confirm the results.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Acute leukemia
|2 Other
650 _ 7 |a Invasive fungal disease
|2 Other
650 _ 7 |a Liposomal amphotericin B
|2 Other
650 _ 7 |a Micafungin
|2 Other
650 _ 7 |a Pediatric
|2 Other
650 _ 7 |a Posaconazole
|2 Other
650 _ 7 |a Primary antifungal prophylaxis
|2 Other
650 _ 7 |a Micafungin
|0 R10H71BSWG
|2 NLM Chemicals
650 _ 7 |a Antifungal Agents
|2 NLM Chemicals
650 _ 7 |a posaconazole
|0 6TK1G07BHZ
|2 NLM Chemicals
650 _ 7 |a Triazoles
|2 NLM Chemicals
650 _ 7 |a Amphotericin B
|0 7XU7A7DROE
|2 NLM Chemicals
650 _ 7 |a liposomal amphotericin B
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Micafungin: administration & dosage
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Child
|2 MeSH
650 _ 2 |a Antifungal Agents: therapeutic use
|2 MeSH
650 _ 2 |a Antifungal Agents: administration & dosage
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Triazoles: administration & dosage
|2 MeSH
650 _ 2 |a Triazoles: therapeutic use
|2 MeSH
650 _ 2 |a Amphotericin B: administration & dosage
|2 MeSH
650 _ 2 |a Amphotericin B: therapeutic use
|2 MeSH
650 _ 2 |a Child, Preschool
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Precursor Cell Lymphoblastic Leukemia-Lymphoma: complications
|2 MeSH
650 _ 2 |a Precursor Cell Lymphoblastic Leukemia-Lymphoma: drug therapy
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: complications
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: drug therapy
|2 MeSH
650 _ 2 |a Infant
|2 MeSH
650 _ 2 |a Mycoses: prevention & control
|2 MeSH
650 _ 2 |a Invasive Fungal Infections: prevention & control
|2 MeSH
700 1 _ |a Ernst, Jana
|b 1
700 1 _ |a Milde, Till
|0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
|b 2
|u dkfz
700 1 _ |a Gruhn, Bernd
|b 3
773 _ _ |a 10.1007/s00432-025-06289-5
|g Vol. 151, no. 8, p. 235
|0 PERI:(DE-600)1459285-X
|n 8
|p 235
|t Journal of cancer research and clinical oncology
|v 151
|y 2025
|x 0301-1585
909 C O |o oai:inrepo02.dkfz.de:304095
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21